trending Market Intelligence /marketintelligence/en/news-insights/trending/9lZNmc7VJxIrnTqu8-l5xA2 content esgSubNav
In This List

Blueprint Medicines starts $275M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Blueprint Medicines starts $275M common stock offering

Blueprint Medicines Corp. started an underwritten public offering of $275 million of its common stock.

The company intends to grant the underwriters an option to buy up to an additional $41.3 million of common shares.

Blueprint plans to use the net proceeds to fund certain clinical trials and the remaining proceeds for working capital and other general corporate purposes.

Goldman Sachs & Co. LLC, Morgan Stanley and Cowen are acting as joint book-running managers, while Canaccord Genuity is acting as co-manager for the offering.